From General Health Science to Occupational Exposure Concerns
For decades, public health communication has centered on broad wellness principles and the general science of disease prevention. This legacy framework has effectively guided populations toward healthier lifestyles and increased awareness of common medical conditions. Within this context, the role of therapeutic interventions—particularly immunotherapies—has emerged as a critical area of focus, especially as treatments become more specialized and their applications expand. One such advancement is the use of Avelumab, a programmed death-ligand 1 (PD-L1) blocking antibody, which has shown efficacy in treating Merkel cell carcinoma, a rare but aggressive skin cancer. As this therapy gains traction in clinical settings, a parallel concern has arisen: the potential for occupational exposure to Avelumab among healthcare workers, pharmaceutical manufacturing personnel, and others who handle the drug. Unlike the general health information that once dominated public discourse, this issue shifts attention to the workplace environment, where inadvertent contact with the agent may pose risks. The transition from broad health science to occupational exposure is subtle but significant. While the public has been educated on the benefits of immunotherapy, less emphasis has been placed on the safety protocols required for those who prepare or administer these drugs. This pivot underscores the need for targeted awareness regarding Avelumab exposure and its possible link to Merkel cell carcinoma risk in occupational settings.
Avelumab and Merkel Cell Carcinoma: Clinical Evidence and Risk Profile
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the JAVELIN Merkel 200 trial, a two-part, single-arm, phase II study in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma has a rising incidence and high mortality (https://pubmed.ncbi.nlm.nih.gov/34445385/). Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors do not respond or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a multicenter study of the prospective skin cancer registry ADOREG, patients with avelumab-refractory MCC were later treated with combined ipilimumab plus nivolumab, and three out of five patients responded according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A retrospective study confirmed that immune checkpoint inhibitors offer durable responses and significant clinical benefit, with avelumab and pembrolizumab currently approved by the U.S. Food and Drug Administration for advanced MCC, yet approximately 50% of patients progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Legal Considerations for Avelumab-Related Injuries in Georgia
From a risk perspective, the adequacy of warnings regarding avelumab and Merkel cell carcinoma is a critical consideration. The prescribing information for avelumab includes warnings about immune-related adverse events, but the specific risk of treatment failure or progression in MCC patients may not be fully emphasized. Given that approximately 50% of patients do not respond or develop irAEs (https://pubmed.ncbi.nlm.nih.gov/34445385/), patients and healthcare providers should be aware of the potential for lack of efficacy and the need for alternative therapies. The timeline between exposure to avelumab and documented harm can vary. In clinical trials, objective responses were observed in about one-third of patients, but for non-responders, progression may occur within weeks to months of starting treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). For patients who develop irAEs, these can occur at any time during treatment and may require discontinuation of therapy. The lack of approved second-line options for avelumab-refractory patients underscores the importance of early monitoring and consideration of alternative immune checkpoint inhibitor combinations, such as ipilimumab plus nivolumab, which have shown activity in this setting (https://pubmed.ncbi.nlm.nih.gov/33439294/). Attorney-related considerations for affected patients include the potential for inadequate warnings about the risk of treatment failure or severe adverse events. Patients who experience progression or debilitating irAEs after avelumab therapy may have legal claims if they were not adequately informed of these risks. The evidence indicates that avelumab is effective in only a subset of patients, and the high rate of non-response (approximately 50%) should be clearly communicated to patients before initiating therapy (https://pubmed.ncbi.nlm.nih.gov/34445385/). Additionally, the timeline between exposure and harm is relevant for legal claims, as patients who suffer harm within a short period after starting avelumab may argue that the drug caused or contributed to their injury. The availability of alternative treatments, such as ipilimumab plus nivolumab for avelumab-refractory patients, may also be relevant in cases where delayed access to such therapies led to worsened outcomes (https://pubmed.ncbi.nlm.nih.gov/33439294/). In summary, avelumab is an important treatment for metastatic Merkel cell carcinoma, but its efficacy is limited to approximately one-third to one-half of patients, and the risk of immune-related adverse events is significant. Patients and attorneys should be aware of the potential for inadequate warnings regarding these risks and the timeline for harm. The evidence supports the need for careful patient selection, monitoring, and consideration of alternative therapies for those who do not respond to avelumab.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Avelumab and how is it used for Merkel cell carcinoma?
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting PD-L1 (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved for the treatment of metastatic Merkel cell carcinoma (MCC) in the USA, EU, and Japan (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the JAVELIN Merkel 200 trial, which showed objective responses in about one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).
What are the risks of treatment failure or adverse events with Avelumab?
Approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors do not respond or develop immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/34445385/). For non-responders, progression may occur within weeks to months of starting treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The prescribing information includes warnings about irAEs, but the specific risk of treatment failure may not be fully emphasized.
Can I file a lawsuit if I was harmed by Avelumab?
Patients who experience progression or debilitating irAEs after avelumab therapy may have legal claims if they were not adequately informed of these risks. The evidence indicates that avelumab is effective in only a subset of patients, and the high rate of non-response (approximately 50%) should be clearly communicated before initiating therapy (https://pubmed.ncbi.nlm.nih.gov/34445385/). An attorney can evaluate whether inadequate warnings or delayed access to alternative treatments contributed to your injury.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.